By modulating myeloid cells in the TME—as demonstrated in preclinical models via stimulation of DC to drive IL-12/TLR9/NK cell-dependent destruction of lymphoma in mice18 and inhibition of M2 macrophages and MDSCs15,16—PG545 offers a complementary approach for use in combination with existing therapies. Here, TLR9 is linked to lymphoma.